Evidence map›Paper›PMID 41683724›Full record

ArticleInternational journal of molecular sciences2026

Pluronic

Kristell Panta Quezada, Gustavo González-Gaitano, Paul Nguewa

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kristell Panta QuezadaDepartment of Microbiology and Parasitology, Navarra Institute for Health Research (IdisNA), University of Navarra, 31080 Pamplona, Spain.ORCID 0000-0002-6631-6767
Gustavo González-GaitanoDepartment of Chemistry, School of Science, University of Navarra, 31080 Pamplona, Spain.ORCID 0000-0002-1477-6710
Paul NguewaDepartment of Microbiology and Parasitology, Navarra Institute for Health Research (IdisNA), University of Navarra, 31080 Pamplona, Spain.ORCID 0000-0002-2193-7316

Funding

Fundación Roviralta Chair "Maria Francisca de Roviralta of Molecular Parasitology, Leishmaniasis and One Health"Ministerio de Ciencia, Innovación y Universidades MICIU/AEI/10.13039/501100011033, PID2023-147765OB-C21, -C22
6 · The paper itself

Abstract

Cutaneous leishmaniasis (CL) is a neglected tropical disease for which current chemotherapeutic options are limited by systemic toxicity (such as hepato-nephrotoxicity, arrhythmia, nausea, vomiting) and difficult administration regimens. Pentamidine (PTM), although effective, exhibits severe dose-limiting adverse effects. Polymeric micelles based on Pluronic

Indexed as

Antiprotozoal AgentsDrug CarriersLeishmania majorLeishmaniasis, CutaneousMicellesNanoparticlesPentamidinePoloxamerAnimalsMiceRAW 264.7 CellsAntiprotozoal AgentsDrug CarriersMicellesPentamidinePoloxamergene expressionleishmaniasismicellar encapsulationpentamidinePluronic® F127

Identifiers

PMID41683724
PMCPMC12898454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.